Tags

Type your tag names separated by a space and hit enter

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Rheumatol Ther. 2023 Oct; 10(5):1127-1146.RT

Abstract

Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40-60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of patients with PsA and patients with moderate-to-severe PsO. This narrative review aims to summarize nail psoriasis data generated from IXE clinical trials in patients with PsA (SPIRIT-P1, SPIRIT-P2, and SPIRIT-H2H) and/or moderate-to-severe PsO (UNCOVER-1, -2, -3, IXORA-R, IXORA-S, and IXORA-PEDS) with an emphasis on head-to-head clinical trial data. Across numerous trials explored, IXE treatment was associated with greater improvement in resolution of nail disease versus comparators at week 24, results which were maintained up to and beyond week 52. Additionally, patients experienced higher rates of resolution of nail disease versus comparators at week 24 and maintained high levels of resolution up to week 52 and beyond. In both PsA and PsO, IXE demonstrated efficacy in treating nail psoriasis, and therefore may be an effective therapy option. Trial Registration: ClinicalTrials.gov identifier UNCOVER-1 (NCT01474512), UNCOVER-2 (NCT01597245), UNCOVER-3 (NCT01646177), IXORA-PEDS (NCT03073200), IXORA-S (NCT02561806), IXORA-R (NCT03573323), SPIRIT-P1 (NCT01695239), SPIRIT-P2 (NCT02349295), SPIRIT-H2H (NCT03151551).

Links

PMC Free PDF

Authors+Show Affiliations

Kirkham BW
Guy's and St Thomas' NHS Foundation Trust, London, UK. bruce.kirkham@gstt.nhs.uk.
Egeberg A
Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Behrens F
Rheumatology Department University Hospital and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune-Mediated Diseases, Goethe University Frankfurt, Frankfurt, Germany.
Pinter A
Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt, Germany.
Merola JF
Dermatology and Medicine, Division of Rheumatology and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Holzkämper T
Eli Lilly and Company, Indianapolis, IN, USA.
Gallo G
Eli Lilly and Company, Indianapolis, IN, USA.
Ng KJ
Eli Lilly and Company, Indianapolis, IN, USA.
Bolce R
Eli Lilly and Company, Indianapolis, IN, USA.
Schuster C
Eli Lilly and Company, Indianapolis, IN, USA. Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Nash P
Rheumatology Research Unit, University of Queensland, Sunshine Coast, QLD, Australia. School of Medicine, Griffith University, Brisbane, Australia.
Puig L
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

37400681

Clinical Trial Links

Clinical trial which this article describes [1]
Clinical trial which this article describes [2]
Clinical trial which this article describes [3]
Clinical trial which this article describes [4]
Clinical trial which this article describes [5]

Citation

Kirkham, Bruce W., et al. "A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis From Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis." Rheumatology and Therapy, vol. 10, no. 5, 2023, pp. 1127-1146.
Kirkham BW, Egeberg A, Behrens F, et al. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Rheumatol Ther. 2023;10(5):1127-1146.
Kirkham, B. W., Egeberg, A., Behrens, F., Pinter, A., Merola, J. F., Holzkämper, T., Gallo, G., Ng, K. J., Bolce, R., Schuster, C., Nash, P., & Puig, L. (2023). A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Rheumatology and Therapy, 10(5), 1127-1146. https://doi.org/10.1007/s40744-023-00553-1
Kirkham BW, et al. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis From Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Rheumatol Ther. 2023;10(5):1127-1146. PubMed PMID: 37400681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. AU - Kirkham,Bruce W, AU - Egeberg,Alexander, AU - Behrens,Frank, AU - Pinter,Andreas, AU - Merola,Joseph F, AU - Holzkämper,Thorsten, AU - Gallo,Gaia, AU - Ng,Khai Jing, AU - Bolce,Rebecca, AU - Schuster,Christopher, AU - Nash,Peter, AU - Puig,Luis, Y1 - 2023/07/03/ PY - 2023/02/22/received PY - 2023/04/13/accepted PY - 2023/7/4/medline PY - 2023/7/4/pubmed PY - 2023/7/3/entrez KW - Ixekizumab KW - Nail psoriasis KW - Plaque psoriasis KW - Psoriatic arthritis SP - 1127 EP - 1146 JF - Rheumatology and therapy JO - Rheumatol Ther VL - 10 IS - 5 N2 - Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40-60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of patients with PsA and patients with moderate-to-severe PsO. This narrative review aims to summarize nail psoriasis data generated from IXE clinical trials in patients with PsA (SPIRIT-P1, SPIRIT-P2, and SPIRIT-H2H) and/or moderate-to-severe PsO (UNCOVER-1, -2, -3, IXORA-R, IXORA-S, and IXORA-PEDS) with an emphasis on head-to-head clinical trial data. Across numerous trials explored, IXE treatment was associated with greater improvement in resolution of nail disease versus comparators at week 24, results which were maintained up to and beyond week 52. Additionally, patients experienced higher rates of resolution of nail disease versus comparators at week 24 and maintained high levels of resolution up to week 52 and beyond. In both PsA and PsO, IXE demonstrated efficacy in treating nail psoriasis, and therefore may be an effective therapy option. Trial Registration: ClinicalTrials.gov identifier UNCOVER-1 (NCT01474512), UNCOVER-2 (NCT01597245), UNCOVER-3 (NCT01646177), IXORA-PEDS (NCT03073200), IXORA-S (NCT02561806), IXORA-R (NCT03573323), SPIRIT-P1 (NCT01695239), SPIRIT-P2 (NCT02349295), SPIRIT-H2H (NCT03151551). SN - 2198-6576 UR - https://www.unboundmedicine.com/medline/citation/37400681/A_Comprehensive_Review_of_Ixekizumab_Efficacy_in_Nail_Psoriasis_from_Clinical_Trials_for_Moderate_to_Severe_Psoriasis_and_Psoriatic_Arthritis_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↑45]

Related Citations

More